Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn July 21, 2021, we received a letter dated July 20, 2021, notifying us that Apotex Inc. (Apotex) submitted an ANDA to the FDA for a generic version of 2.2 mg base/ml Fintepla (fenfluramine hydrochloride) that contains Paragraph IV certifications with respect to two of our patents covering Fintepla, U.S. Patent Nos. 10,603,290, expiration date August 2, 2037; and 10,452,815, expiration date October 22, 2039. These patents are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for Fintepla. The certifications allege these patents are invalid or will not be infringed by the manufacture, use or sale of Apotex’s fenfluramine hydrochloride oral solution, 2.2 mg base/ml product. In the United States, approved ANDA generic drugs are usually interchangeable with the branded innovator drug. We anticipate initiating litigation against Apotex over the validity and infringement of the patents covering Fintepla.